{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:58:45Z","timestamp":1787590725597,"version":"build-2736575974"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Guizhou Science and Technology Department","doi-asserted-by":"crossref","award":["Grant No. ZK2021380"],"award-info":[{"award-number":["Grant No. ZK2021380"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Doctoral Foundation of the Affiliated Hospital of Zunyi Medical University","award":["Grant No. 201801"],"award-info":[{"award-number":["Grant No. 201801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06949-7","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:33:46Z","timestamp":1761046426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Jian","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chea","family":"Kimhoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7808-0764","authenticated-orcid":false,"given":"Shulian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"3","key":"6949_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"6949_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024;332(12):1001\u201310.","journal-title":"JAMA"},{"issue":"10","key":"6949_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","volume":"50","author":"JK Lee","year":"2018","unstructured":"Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018;50(10):1399\u2013411.","journal-title":"Nat Genet"},{"issue":"7467","key":"6949_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338\u201345.","journal-title":"Nature"},{"issue":"5","key":"6949_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase iii randomised checkmate 9ER trial. ESMO Open. 2024;9(5): 102994.","journal-title":"ESMO Open"},{"issue":"5","key":"6949_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol. 2023;84(5):449\u201354.","journal-title":"Eur Urol"},{"issue":"1","key":"6949_CR7","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. 2023 CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"2023 CA Cancer J Clin"},{"issue":"10451","key":"6949_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404(10451):476\u201391.","journal-title":"Lancet"},{"issue":"5","key":"6949_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021;39(5):632\u201348 (e8).","journal-title":"Cancer Cell"},{"issue":"4","key":"6949_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","volume":"169","author":"S Chevrier","year":"2017","unstructured":"Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al. An immune atlas of clear cell renal cell carcinoma. Cell. 2017;169(4):736\u201349 (e18).","journal-title":"Cell"},{"issue":"9","key":"6949_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","volume":"74","author":"JL Wilding","year":"2014","unstructured":"Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74(9):2377\u201384.","journal-title":"Cancer Res"},{"issue":"7718","key":"6949_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","volume":"560","author":"U Ben-David","year":"2018","unstructured":"Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560(7718):325\u201330.","journal-title":"Nature"},{"issue":"1","key":"6949_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39\u201353.","journal-title":"Cell"},{"issue":"7244","key":"6949_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature07935","volume":"459","author":"T Sato","year":"2009","unstructured":"Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262\u20135.","journal-title":"Nature"},{"issue":"6378","key":"6949_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136.","journal-title":"Science"},{"issue":"1","key":"6949_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26(1):17\u201326 (e6).","journal-title":"Cell Stem Cell"},{"issue":"8","key":"6949_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41419-024-06960-8","volume":"15","author":"F Ren","year":"2024","unstructured":"Ren F, Wang L, Wang Y, Wang J, Wang Y, Song X, et al. Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs. Cell Death Dis. 2024;15(8):571.","journal-title":"Cell Death Dis"},{"issue":"1","key":"6949_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12894-024-01511-x","volume":"24","author":"Q Chen","year":"2024","unstructured":"Chen Q, Sun X, Li Y, Yang X, Yang X, Xu H, et al. The potential of organoids in renal cell carcinoma research. BMC Urol. 2024;24(1):120.","journal-title":"BMC Urol"},{"issue":"6124","key":"6949_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/327721a0","volume":"327","author":"B Zbar","year":"1987","unstructured":"Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327(6124):721\u20134.","journal-title":"Nature"},{"issue":"1","key":"6949_CR20","first-page":"27","volume":"56","author":"H Moch","year":"1996","unstructured":"Moch H, Presti JC Jr, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56(1):27\u201330.","journal-title":"Cancer Res"},{"key":"6949_CR21","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 4;499(7456):43-9.","DOI":"10.1038\/nature12222"},{"issue":"1","key":"6949_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000134448","volume":"75","author":"M Bentz","year":"1996","unstructured":"Bentz M, Bergerheim US, Li C, Joos S, Werner CA, Baudis M, et al. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet. 1996;75(1):17\u201321.","journal-title":"Cytogenet Cell Genet"},{"issue":"1","key":"6949_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68\u201373.","journal-title":"Nat Genet"},{"issue":"7","key":"6949_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.970","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Xu H, Yu L, Wang J, Meng Q, Mei H, et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med. 2022;12(7): e970.","journal-title":"Clin Transl Med"},{"issue":"1","key":"6949_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0165-4608(95)00167-0","volume":"86","author":"T Shuin","year":"1996","unstructured":"Shuin T, Kondo K, Sakai N, Kaneko S, Yao M, Nagashima Y, et al. A case of chromophobe renal cell carcinoma associated with low chromosome number and microsatellite instability. Cancer Genet Cytogenet. 1996;86(1):69\u201371.","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"6949_CR26","first-page":"356","volume":"145","author":"MR Speicher","year":"1994","unstructured":"Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145(2):356\u201364.","journal-title":"Am J Pathol"},{"issue":"19","key":"6949_CR27","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1158\/0008-5472.CAN-17-0986","volume":"77","author":"M Sun","year":"2017","unstructured":"Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, et al. HNF1B loss exacerbates the development of chromophobe renal cell carcinomas. Cancer Res. 2017;77(19):5313\u201326.","journal-title":"Cancer Res"},{"issue":"12","key":"6949_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/ars.2015.6569","volume":"25","author":"K Shanmugasundaram","year":"2016","unstructured":"Shanmugasundaram K, Block K. Renal carcinogenesis, tumor heterogeneity, and reactive oxygen species: tactics evolved. Antioxid Redox Signal. 2016;25(12):685\u2013701.","journal-title":"Antioxid Redox Signal"},{"issue":"18","key":"6949_CR29","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1158\/0008-5472.CAN-20-0754","volume":"80","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Clima R, Busch J, Rabien A, Kilic E, Villegas SL, et al. Decreased mitochondrial DNA content drives OXPHOS dysregulation in chromophobe renal cell carcinoma. Cancer Res. 2020;80(18):3830\u201340.","journal-title":"Cancer Res"},{"issue":"2","key":"6949_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(2):515-28e17.","journal-title":"Cell"},{"issue":"6","key":"6949_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","volume":"18","author":"M Fujii","year":"2016","unstructured":"Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016;18(6):827\u201338.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"6949_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, et al. The 2022 world health organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458\u201368.","journal-title":"Eur Urol"},{"issue":"2","key":"6949_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41568-018-0095-3","volume":"19","author":"U Ben-David","year":"2019","unstructured":"Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019;19(2):97\u2013109.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"6949_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404\u201316.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"6949_CR35","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3390\/cells10071718","volume":"10","author":"T Thalheim","year":"2021","unstructured":"Thalheim T, Siebert S, Quaas M, Herberg M, Schweiger MR, Aust G, et al. Epigenetic drifts during long-term intestinal organoid culture. Cells. 2021;10(7):1718.","journal-title":"Cells"},{"issue":"1","key":"6949_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","volume":"11","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yuan F, Zuo X, Li M. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments. Cell Death Discov. 2025;11(1):222.","journal-title":"Cell Death Discov"},{"issue":"513","key":"6949_CR37","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11(513):eaay2574.","journal-title":"Sci Transl Med"},{"issue":"7","key":"6949_CR38","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972\u201388 (e16).","journal-title":"Cell"},{"issue":"4","key":"6949_CR39","doi-asserted-by":"publisher","first-page":"pbac028","DOI":"10.1093\/pcmedi\/pbac028","volume":"5","author":"Y Xue","year":"2022","unstructured":"Xue Y, Wang B, Tao Y, Xia J, Yuan K, Zheng J, et al. Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. Precis Clin Med. 2022;5(4):pbac028.","journal-title":"Precis Clin Med"},{"issue":"2","key":"6949_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4111\/icu.2020.61.2.216","volume":"61","author":"JC Na","year":"2020","unstructured":"Na JC, Kim JH, Kim SY, Gu YR, Jun DY, Lee HH, et al. Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma. Investig Clin Urol. 2020;61(2):216\u201323.","journal-title":"Investig Clin Urol"},{"key":"6949_CR41","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3389\/fonc.2020.01775","volume":"10","author":"LK Esser","year":"2020","unstructured":"Esser LK, Branchi V, Leonardelli S, Pelusi N, Simon AG, Klumper N, et al. Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy. Front Oncol. 2020;10:1775.","journal-title":"Front Oncol"},{"issue":"1","key":"6949_CR42","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1186\/s12885-018-5049-3","volume":"18","author":"P Rochigneux","year":"2018","unstructured":"Rochigneux P, Thomassin-Piana J, Laibe S, Brunelle S, Salem N, Escudier B, et al. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with met amplification: a case report and literature review. BMC Cancer. 2018;18(1):1159.","journal-title":"BMC Cancer"},{"issue":"5","key":"6949_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.euf.2023.03.005","volume":"9","author":"S Angori","year":"2023","unstructured":"Angori S, Banaei-Esfahani A, Muhlbauer K, Bolck HA, Kahraman A, Karakulak T, et al. Ex vivo drug testing in patient-derived papillary renal cancer cells reveals EGFR and the BCL2 family as therapeutic targets. Eur Urol Focus. 2023;9(5):751\u20139.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6949_CR44","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/ad927f","volume":"11","author":"UM Jahan","year":"2024","unstructured":"Jahan UM, Blevins B, Minko S, Reukov VV. Advancing biomedical applications: antioxidant and biocompatible cerium oxide nanoparticle-integrated poly-epsilon-caprolactone fibers. Biomed Phys Eng Express. 2024;11(1): 015020.","journal-title":"Biomed Phys Eng Express"},{"issue":"9","key":"6949_CR45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant P53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674\u201387.","journal-title":"J Mol Cell Biol"},{"key":"6949_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semcancer.2018.11.006","volume":"53","author":"TB Steinbichler","year":"2018","unstructured":"Steinbichler TB, Dudas J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156\u201367.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"6949_CR47","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc. 2020;15(10):3380\u2013409.","journal-title":"Nat Protoc"},{"issue":"5","key":"6949_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107588","volume":"31","author":"KK Dijkstra","year":"2020","unstructured":"Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF, Kaing S, et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep. 2020;31(5): 107588.","journal-title":"Cell Rep"},{"issue":"8","key":"6949_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101408","volume":"23","author":"AE Vilgelm","year":"2020","unstructured":"Vilgelm AE, Bergdorf K, Wolf M, Bharti V, Shattuck-Brandt R, Blevins A, et al. Fine-needle aspiration-based patient-derived cancer organoids. iScience. 2020;23(8): 101408.","journal-title":"iScience"},{"issue":"8","key":"6949_CR50","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/onc.2016.272","volume":"36","author":"JM Thompson","year":"2017","unstructured":"Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, et al. Rho-associated kinase 1 inhibition is synthetically lethal with von hippel-lindau deficiency in clear cell renal cell carcinoma. Oncogene. 2017;36(8):1080\u20139.","journal-title":"Oncogene"},{"issue":"4","key":"6949_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12079-022-00666-2","volume":"16","author":"A Nyga","year":"2022","unstructured":"Nyga A, Stamati K, Redondo PA, Azimi T, Feber A, Neves JB, et al. Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells. J Cell Commun Signal. 2022;16(4):637\u201348.","journal-title":"J Cell Commun Signal"},{"issue":"12","key":"6949_CR52","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/gels8120821","volume":"8","author":"L Hipwood","year":"2022","unstructured":"Hipwood L, Clegg J, Weekes A, Davern JW, Dargaville TR, Meinert C, et al. Semi-synthetic click-gelatin hydrogels as tunable platforms for 3D cancer cell culture. Gels. 2022;8(12):821.","journal-title":"Gels"},{"key":"6949_CR53","doi-asserted-by":"publisher","first-page":"rbaf038","DOI":"10.1093\/rb\/rbaf038","volume":"12","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang X, Zhang W, Tang J, Liu J. Rational design matrix materials for organoid development and application in biomedicine. 2025;12:rbaf038.","journal-title":"Regen Biomater"},{"issue":"1","key":"6949_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12894-025-01816-5","volume":"25","author":"M Pashai Fakhri","year":"2025","unstructured":"Pashai Fakhri M, Serth J, Brasen JH, Ivanyi P, Kuczyk MA, Tezval H. Chromophobe renal cell carcinoma-a rare kidney cancer with limited therapy options: a narrative review. BMC Urol. 2025;25(1):147.","journal-title":"BMC Urol"},{"issue":"3","key":"6949_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/biom10030361","volume":"10","author":"M Cordani","year":"2020","unstructured":"Cordani M, Butera G, Pacchiana R, Masetto F, Mullappilly N, Riganti C, et al. Mutant P53-associated molecular mechanisms of ROS regulation in cancer cells. Biomolecules. 2020;10(3):361.","journal-title":"Biomolecules"},{"issue":"6444","key":"6949_CR56","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952\u20135.","journal-title":"Science"},{"issue":"7","key":"6949_CR57","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"6949_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41576-018-0051-9","volume":"19","author":"G Rossi","year":"2018","unstructured":"Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat Rev Genet. 2018;19(11):671\u201387.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"6949_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cell.2015.02.045","volume":"161","author":"DF Lee","year":"2015","unstructured":"Lee DF, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, et al. Modeling familial cancer with induced pluripotent stem cells. Cell. 2015;161(2):240\u201354.","journal-title":"Cell"},{"issue":"6","key":"6949_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.stem.2021.03.022","volume":"28","author":"L Huang","year":"2021","unstructured":"Huang L, Desai R, Conrad DN, Leite NC, Akshinthala D, Lim CM, et al. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell. 2021;28(6):1090\u201310 (e46).","journal-title":"Cell Stem Cell"},{"issue":"4","key":"6949_CR61","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.stem.2020.07.022","volume":"27","author":"AFM Dost","year":"2020","unstructured":"Dost AFM, Moye AL, Vedaie M, Tran LM, Fung E, Heinze D, et al. Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells. Cell Stem Cell. 2020;27(4):663\u201378 (e8).","journal-title":"Cell Stem Cell"},{"issue":"3","key":"6949_CR62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.molmed.2017.01.001","volume":"23","author":"R Morizane","year":"2017","unstructured":"Morizane R, Bonventre JV. Kidney organoids: a translational journey. Trends Mol Med. 2017;23(3):246\u201363.","journal-title":"Trends Mol Med"},{"issue":"7","key":"6949_CR63","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","volume":"20","author":"RG Rowe","year":"2019","unstructured":"Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20(7):377\u201388.","journal-title":"Nat Rev Genet"},{"issue":"10","key":"6949_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"6949_CR65","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.stem.2018.10.010","volume":"23","author":"H Wu","year":"2018","unstructured":"Wu H, Uchimura K, Donnelly EL, Kirita Y, Morris SA, Humphreys BD. Comparative analysis and refinement of human PSC-derived kidney organoid differentiation with single-cell transcriptomics. Cell Stem Cell. 2018;23(6):869\u201381 (e8).","journal-title":"Cell Stem Cell"},{"issue":"41","key":"6949_CR66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408549121","volume":"121","author":"LA Stransky","year":"2024","unstructured":"Stransky LA, Gao W, Schmidt LS, Bi K, Ricketts CJ, Ramesh V, et al. Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: initial experience and lessons learned. Proc Natl Acad Sci USA. 2024;121(41): e2408549121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"6949_CR67","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41419-019-1453-0","volume":"10","author":"L Grassi","year":"2019","unstructured":"Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis ML, Addario A, et al. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019;10(3):201.","journal-title":"Cell Death Dis"},{"issue":"1","key":"6949_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1574888X113086660068","volume":"9","author":"Y Tan","year":"2014","unstructured":"Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther. 2014;9(1):63\u201372.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"11","key":"6949_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113420","volume":"42","author":"K Takeuchi","year":"2023","unstructured":"Takeuchi K, Tabe S, Takahashi K, Aoshima K, Matsuo M, Ueno Y, et al. Incorporation of human IPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Cell Rep. 2023;42(11): 113420.","journal-title":"Cell Rep"},{"issue":"1","key":"6949_CR70","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13287-024-03862-6","volume":"15","author":"C Kustermann","year":"2024","unstructured":"Kustermann C, Narbute K, Movcana V, Parfejevs V, Rumnieks F, Kaukis P, et al. IPSC-derived lung and lung cancer organoid model to evaluate cisplatin encapsulated autologous IPSC-derived mesenchymal stromal cell-isolated extracellular vesicles. Stem Cell Res Ther. 2024;15(1):246.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"6949_CR71","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41587-019-0048-8","volume":"37","author":"F Schutgens","year":"2019","unstructured":"Schutgens F, Rookmaaker MB, Margaritis T, Rios A, Ammerlaan C, Jansen J, et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat Biotechnol. 2019;37(3):303\u201313.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"6949_CR72","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","volume":"130","author":"BJ Viergever","year":"2024","unstructured":"Viergever BJ, Raats DAE, Geurts V, Mullenders J, Jonges TN, van der Heijden MS, et al. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. Br J Cancer. 2024;130(3):369\u201379.","journal-title":"Br J Cancer"},{"issue":"17","key":"6949_CR73","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/cells12172188","volume":"12","author":"S Walz","year":"2023","unstructured":"Walz S, Pollehne P, Geng R, Schneider J, Maas M, Aicher WK, et al. A protocol for organoids from the urine of bladder cancer patients. Cells. 2023;12(17):2188.","journal-title":"Cells"},{"issue":"12","key":"6949_CR74","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/cells12121630","volume":"12","author":"V Pizzuti","year":"2023","unstructured":"Pizzuti V, Donadei C, Balducelli E, Conte D, Gessaroli E, Paris F, et al. Urine-derived renal epithelial cells (URECs) from transplanted kidneys as a promising immunomodulatory cell population. Cells. 2023;12(12):1630.","journal-title":"Cells"},{"issue":"15","key":"6949_CR75","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","volume":"24","author":"OA Zill","year":"2018","unstructured":"Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018;24(15):3528\u201338.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"6949_CR76","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/jnci\/91.23.2028","volume":"91","author":"CF Eisenberger","year":"1999","unstructured":"Eisenberger CF, Schoenberg M, Enger C, Hortopan S, Shah S, Chow NH, et al. Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst. 1999;91(23):2028\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"6949_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku606","volume":"42","author":"DJ Eastburn","year":"2014","unstructured":"Eastburn DJ, Sciambi A, Abate AR. Identification and genetic analysis of cancer cells with PCR-activated cell sorting. Nucleic Acids Res. 2014;42(16): e128.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"6949_CR78","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2012.02.025","volume":"148","author":"X Xu","year":"2012","unstructured":"Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148(5):886\u201395.","journal-title":"Cell"},{"issue":"14","key":"6949_CR79","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers13143466","volume":"13","author":"I Belhabib","year":"2021","unstructured":"Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular matrices and cancer-associated fibroblasts: Targets for cancer diagnosis and therapy?. Cancers (Basel). 2021;13(14):3466.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6949_CR80","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1371\/journal.pbio.0020007","volume":"2","author":"HY Chang","year":"2004","unstructured":"Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2(2):E7.","journal-title":"PLoS Biol"},{"issue":"10","key":"6949_CR81","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1073\/pnas.0409462102","volume":"102","author":"HY Chang","year":"2005","unstructured":"Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005;102(10):3738\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"6949_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","volume":"21","author":"BL LeSavage","year":"2022","unstructured":"LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. Next-generation cancer organoids. Nat Mater. 2022;21(2):143\u201359.","journal-title":"Nat Mater"},{"issue":"1","key":"6949_CR83","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/ncomms1711","volume":"3","author":"SI Fraley","year":"2012","unstructured":"Fraley SI, Feng Y, Giri A, Longmore GD, Wirtz D. Dimensional and temporal controls of three-dimensional cell migration by zyxin and binding partners. Nat Commun. 2012;3(1):719.","journal-title":"Nat Commun"},{"issue":"7630","key":"6949_CR84","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nature20168","volume":"539","author":"N Gjorevski","year":"2016","unstructured":"Gjorevski N, Sachs N, Manfrin A, Giger S, Bragina ME, Ordonez-Moran P, et al. Designer matrices for intestinal stem cell and organoid culture. Nature. 2016;539(7630):560\u20134.","journal-title":"Nature"},{"issue":"11","key":"6949_CR85","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/ncb3632","volume":"19","author":"R Cruz-Acuna","year":"2017","unstructured":"Cruz-Acuna R, Quiros M, Farkas AE, Dedhia PH, Huang S, Siuda D, et al. Synthetic hydrogels for human intestinal organoid generation and colonic wound repair. Nat Cell Biol. 2017;19(11):1326\u201335.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"6949_CR86","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41592-019-0325-y","volume":"16","author":"KA Homan","year":"2019","unstructured":"Homan KA, Gupta N, Kroll KT, Kolesky DB, Skylar-Scott M, Miyoshi T, et al. Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods. 2019;16(3):255\u201362.","journal-title":"Nat Methods"},{"key":"6949_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123349","volume":"322","author":"S Clerkin","year":"2025","unstructured":"Clerkin S, Singh K, Davis JL, Treacy NJ, Krupa I, Reynaud EG, et al. Tuneable gelatin methacryloyl (GelMA) hydrogels for the directed specification of renal cell types for HiPSC-derived kidney organoid maturation. Biomaterials. 2025;322: 123349.","journal-title":"Biomaterials"},{"issue":"3","key":"6949_CR88","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jbm.b.35169","volume":"111","author":"A Talaei","year":"2023","unstructured":"Talaei A, O\u2019Connell CD, Sayyar S, Maher M, Yue Z, Choong PF, et al. Optimizing the composition of gelatin methacryloyl and hyaluronic acid methacryloyl hydrogels to maximize mechanical and transport properties using response surface methodology. J Biomed Mater Res B Appl Biomater. 2023;111(3):526\u201337.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"22","key":"6949_CR89","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1039\/D1BM01280K","volume":"9","author":"X Yang","year":"2021","unstructured":"Yang X, Wang Y, Mao T, Wang Y, Liu R, Yu L, et al. An oxygen-enriched thermosensitive hydrogel for the relief of a hypoxic tumor microenvironment and enhancement of radiotherapy. Biomater Sci. 2021;9(22):7471\u201382.","journal-title":"Biomater Sci"},{"key":"6949_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100818","volume":"23","author":"B Gabbin","year":"2023","unstructured":"Gabbin B, Meraviglia V, Angenent ML, Ward-van Oostwaard D, Sol W, Mummery CL, et al. Heart and kidney organoids maintain organ-specific function in a microfluidic system. Mater Today Bio. 2023;23: 100818.","journal-title":"Mater Today Bio"},{"issue":"1","key":"6949_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/beta-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6949_CR92","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.devcel.2014.03.015","volume":"29","author":"YL Huang","year":"2014","unstructured":"Huang YL, Niehrs C. Polarized Wnt signaling regulates ectodermal cell fate in xenopus. Dev Cell. 2014;29(2):250\u20137.","journal-title":"Dev Cell"},{"key":"6949_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-12-394592-1.00003-X","volume":"101","author":"H Sawa","year":"2012","unstructured":"Sawa H. Control of cell polarity and asymmetric division in C. Elegans Curr Top Dev Biol. 2012;101:55\u201376.","journal-title":"Elegans Curr Top Dev Biol"},{"issue":"7653","key":"6949_CR94","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature22313","volume":"545","author":"KS Yan","year":"2017","unstructured":"Yan KS, Janda CY, Chang J, Zheng GXY, Larkin KA, Luca VC, et al. Non-equivalence of Wnt and R-spondin ligands during Lgr5($$^+$$) intestinal stem-cell self-renewal. Nature. 2017;545(7653):238\u201342.","journal-title":"Nature"},{"issue":"9","key":"6949_CR95","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1172\/JCI72340","volume":"124","author":"PR de Jong","year":"2014","unstructured":"de Jong PR, Takahashi N, Harris AR, Lee J, Bertin S, Jeffries J, et al. Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. J Clin Invest. 2014;124(9):3793\u2013806.","journal-title":"J Clin Invest"},{"issue":"13","key":"6949_CR96","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","volume":"20","author":"L Albiges","year":"2014","unstructured":"Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of PRCC with CGH array and matching gene expression array. Clin Cancer Res. 2014;20(13):3411\u201321.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6949_CR97","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0046-8177(97)90198-2","volume":"28","author":"H Moch","year":"1997","unstructured":"Moch H, Sauter G, Buchholz N, Gasser TC, Bubendorf L, Waldman FM, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol. 1997;28(11):1255\u20139.","journal-title":"Hum Pathol"},{"issue":"1","key":"6949_CR98","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41467-025-58439-5","volume":"16","author":"D Lu","year":"2025","unstructured":"Lu D, Zheng Y, Yi X, Hao J, Zeng X, Han L, et al. Identifying potential risk genes for clear cell renal cell carcinoma with deep reinforcement learning. Nat Commun. 2025;16(1):3591.","journal-title":"Nat Commun"},{"issue":"4","key":"6949_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102359","volume":"23","author":"M Alchoueiry","year":"2025","unstructured":"Alchoueiry M, Mansour H, Khabibullin D, Han T, Chaturantabut S, Bzeih W, et al. Targeting KIT with antibody-drug conjugates in chromophobe renal cell carcinoma. Clin Genitourin Cancer. 2025;23(4): 102359.","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"6949_CR100","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586\u201397.","journal-title":"Cell"},{"issue":"22","key":"6949_CR101","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.3390\/cancers14225617","volume":"14","author":"V Gassl","year":"2022","unstructured":"Gassl V, Aberle MR, Boonen B, Vaes RDW, Olde Damink SWM, Rensen SS. Chemosensitivity of 3D pancreatic cancer organoids is not affected by transformation to 2D Culture or switch to physiological culture medium. Cancers (Basel). 2022;14(22):5617.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6949_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164438","volume":"11","author":"JR Cooper","year":"2016","unstructured":"Cooper JR, Abdullatif MB, Burnett EC, Kempsell KE, Conforti F, Tolley H, et al. Long term culture of the A549 cancer cell line promotes multilamellar body formation and differentiation towards an alveolar type ii pneumocyte phenotype. PLoS ONE. 2016;11(10): e0164438.","journal-title":"PLoS ONE"},{"key":"6949_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101485","volume":"52","author":"S Zhao","year":"2021","unstructured":"Zhao S, Peralta RM, Avina-Ochoa N, Delgoffe GM, Kaech SM. Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. Semin Immunol. 2021;52: 101485.","journal-title":"Semin Immunol"},{"issue":"1","key":"6949_CR104","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10238-024-01390-4","volume":"24","author":"G Wu","year":"2024","unstructured":"Wu G, Li T, Chen Y, Ye S, Zhou S, Tian X, et al. Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma. Clin Exp Med. 2024;24(1):152.","journal-title":"Clin Exp Med"},{"key":"6949_CR105","doi-asserted-by":"crossref","unstructured":"Bacigalupa ZA, Arner EN, Vlach LM, Wolf MM, Brown WA, Krystofiak ES, et al. HIF-2alpha expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. J Clin Invest. 2024 Jun 17;134(12).","DOI":"10.1172\/JCI164249"},{"key":"6949_CR106","doi-asserted-by":"publisher","first-page":"1434981","DOI":"10.3389\/or.2024.1434981","volume":"18","author":"Z Li","year":"2024","unstructured":"Li Z, You Y, Feng B, Chen J, Gao H, Li F. Construction methods and latest applications of kidney cancer organoids. Oncol Rev. 2024;18:1434981.","journal-title":"Oncol Rev"},{"issue":"5","key":"6949_CR107","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and barrett\u2019s epithelium. Gastroenterology. 2011;141(5):1762\u201372.","journal-title":"Gastroenterology"},{"issue":"3","key":"6949_CR108","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.7150\/thno.91362","volume":"14","author":"J Lv","year":"2024","unstructured":"Lv J, Du X, Wang M, Su J, Wei Y, Xu C. Construction of tumor organoids and their application to cancer research and therapy. Theranostics. 2024;14(3):1101\u201325.","journal-title":"Theranostics"},{"key":"6949_CR109","first-page":"142","volume":"21","author":"NJ Treacy","year":"2023","unstructured":"Treacy NJ, Clerkin S, Davis JL, Kennedy C, Miller AF, Saiani A, et al. Growth and differentiation of human induced pluripotent stem cell (hiPSC)-derived kidney organoids using fully synthetic peptide hydrogels. Bioact Mater. 2023;21:142\u201356.","journal-title":"Bioact Mater"},{"issue":"12","key":"6949_CR110","doi-asserted-by":"publisher","first-page":"E2293","DOI":"10.1073\/pnas.1612906114","volume":"114","author":"YS Zhang","year":"2017","unstructured":"Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci USA. 2017;114(12):E2293\u2013302.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"6949_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jcp.24683","volume":"230","author":"M Ravi","year":"2015","unstructured":"Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FD. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16\u201326.","journal-title":"J Cell Physiol"},{"issue":"8","key":"6949_CR112","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760\u201372.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"6949_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136758","volume":"10","author":"CA Batchelder","year":"2015","unstructured":"Batchelder CA, Martinez ML, Duru N, Meyers FJ, Tarantal AF. Three dimensional culture of human renal cell carcinoma organoids. PLoS ONE. 2015;10(8): e0136758.","journal-title":"PLoS ONE"},{"issue":"3","key":"6949_CR114","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/abec2c","volume":"13","author":"G Decante","year":"2021","unstructured":"Decante G, Costa JB, Silva-Correia J, Collins MN, Reis RL, Oliveira JM. Engineering bioinks for 3D bioprinting. Biofabrication. 2021;13(3): 032001.","journal-title":"Biofabrication"},{"issue":"1","key":"6949_CR115","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/aca05d","volume":"18","author":"CC Clark","year":"2022","unstructured":"Clark CC, Yoo KM, Sivakumar H, Strumpf K, Laxton AW, Tatter SB, et al. Immersion bioprinting of hyaluronan and collagen bioink-supported 3d patient-derived brain tumor organoids. Biomed Mater. 2022;18(1): 015014.","journal-title":"Biomed Mater"},{"issue":"9","key":"6949_CR116","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41419-023-06133-z","volume":"14","author":"I Seraudie","year":"2023","unstructured":"Seraudie I, Pillet C, Cesana B, Bazelle P, Jeanneret F, Evrard B, et al. A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in renal cell carcinoma. Cell Death Dis. 2023;14(9):622.","journal-title":"Cell Death Dis"},{"key":"6949_CR117","doi-asserted-by":"publisher","first-page":"204173142413003","DOI":"10.1177\/20417314241300386","volume":"15","author":"X Guo","year":"2024","unstructured":"Guo X, Liu B, Zhang Y, Cheong S, Xu T, Lu F, et al. Decellularized extracellular matrix for organoid and engineered organ culture. J Tissue Eng. 2024;15:20417314241300384.","journal-title":"J Tissue Eng"},{"issue":"5","key":"6949_CR118","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.tibtech.2022.10.009","volume":"41","author":"T Zandrini","year":"2023","unstructured":"Zandrini T, Florczak S, Levato R, Ovsianikov A. Breaking the resolution limits of 3D bioprinting: future opportunities and present challenges. Trends Biotechnol. 2023;41(5):604\u201314.","journal-title":"Trends Biotechnol"},{"issue":"19","key":"6949_CR119","doi-asserted-by":"publisher","first-page":"10887","DOI":"10.1021\/acs.chemrev.0c00027","volume":"120","author":"RW Barrs","year":"2020","unstructured":"Barrs RW, Jia J, Silver SE, Yost M, Mei Y. Biomaterials for bioprinting microvasculature. Chem Rev. 2020;120(19):10887\u2013949.","journal-title":"Chem Rev"},{"issue":"3","key":"6949_CR120","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/gels8030179","volume":"8","author":"A Fatimi","year":"2022","unstructured":"Fatimi A, Okoro OV, Podstawczyk D, Siminska-Stanny J, Shavandi A. Natural hydrogel-based bio-inks for 3D bioprinting in tissue engineering: a review. Gels. 2022;8(3):179.","journal-title":"Gels"},{"issue":"1","key":"6949_CR121","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12951-024-02759-z","volume":"22","author":"X Zhao","year":"2024","unstructured":"Zhao X, Li N, Zhang Z, Hong J, Zhang X, Hao Y, et al. Beyond hype: unveiling the real challenges in clinical translation of 3D printed bone scaffolds and the fresh prospects of bioprinted organoids. J Nanobiotechnol. 2024;22(1):500.","journal-title":"J Nanobiotechnol"},{"key":"6949_CR122","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.urology.2018.09.018","volume":"124","author":"MA Liss","year":"2019","unstructured":"Liss MA, Chen Y, Rodriguez R, Pruthi D, Johnson-Pais T, Wang H, et al. Immunogenic heterogeneity of renal cell carcinoma with venous tumor thrombus. Urology. 2019;124:168\u201373.","journal-title":"Urology"},{"issue":"1","key":"6949_CR123","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang S, Sun H, Xu L. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discov. 2025;11(1):186.","journal-title":"Cell Death Discov"},{"issue":"12","key":"6949_CR124","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.3390\/jcm12123888","volume":"12","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, et al. Cellular and molecular players in the tumor microenvironment of renal cell carcinoma. J Clin Med. 2023;12(12):3888.","journal-title":"J Clin Med"},{"issue":"12","key":"6949_CR125","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/bios12121177","volume":"12","author":"A Ozcelik","year":"2022","unstructured":"Ozcelik A, Abas BI, Erdogan O, Cevik E, Cevik O. On-chip organoid formation to study CXCR4\/CXCL-12 chemokine microenvironment responses for renal cancer drug testing. Biosensors (Basel). 2022;12(12):1177.","journal-title":"Biosensors (Basel)"},{"issue":"1","key":"6949_CR126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, et al. Tumor organoid-T-cell coculture systems. Nat Protoc. 2020;15(1):15\u201339.","journal-title":"Nat Protoc"},{"issue":"1","key":"6949_CR127","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-023-02653-w","volume":"42","author":"P Mu","year":"2023","unstructured":"Mu P, Zhou S, Lv T, Xia F, Shen L, Wan J, et al. Newly developed 3D in vitro models to study tumor-immune interaction. J Exp Clin Cancer Res. 2023;42(1):81.","journal-title":"J Exp Clin Cancer Res"},{"key":"6949_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.770465","volume":"13","author":"CP Sun","year":"2022","unstructured":"Sun CP, Lan HR, Fang XL, Yang XY, Jin KT. Organoid models for precision cancer immunotherapy. Front Immunol. 2022;13: 770465.","journal-title":"Front Immunol"},{"issue":"1","key":"6949_CR129","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo J, Guo M, Huang M, Liu Y, Qian Y, Liu Q, et al. Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via C-Myc\/NRF1 activation. Signal Transduct Target Ther. 2025;10(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6949_CR130","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","volume":"5","author":"B Breznik","year":"2022","unstructured":"Breznik B, Ko MW, Tse C, Chen PC, Senjor E, Majc B, et al. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres. Commun Biol. 2022;5(1):436.","journal-title":"Commun Biol"},{"issue":"7","key":"6949_CR131","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.62347\/BQFH7352","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Zhang B, Cui Y, Song H, Shang D. In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy. Am J Cancer Res. 2024;14(7):3222\u201340.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"6949_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006290","volume":"11","author":"L Magre","year":"2023","unstructured":"Magre L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023;11(5): e006290.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6949_CR133","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41420-025-02407-x","volume":"11","author":"J Wang","year":"2025","unstructured":"Wang J, Tao X, Zhu J, Dai Z, Du Y, Xie Y, et al. Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity. Cell Death Discov. 2025;11(1):195.","journal-title":"Cell Death Discov"},{"issue":"7","key":"6949_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011733","volume":"13","author":"Q Si","year":"2025","unstructured":"Si Q, Tao S, Wu J, Ma J, Li Z, Feng X, et al. Tumor organoids in immunotherapy: from disease modeling to translational research. J Immunother Cancer. 2025;13(7): e011733.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"6949_CR135","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895\u2013905.","journal-title":"Int J Cancer"},{"issue":"1","key":"6949_CR136","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"key":"6949_CR137","doi-asserted-by":"publisher","first-page":"1053920","DOI":"10.3389\/fimmu.2023.1053920","volume":"14","author":"E Strating","year":"2023","unstructured":"Strating E, Verhagen MP, Wensink E, Dunnebach E, Wijler L, Aranguren I, et al. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front Immunol. 2023;14:1053920.","journal-title":"Front Immunol"},{"issue":"1","key":"6949_CR138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18(1):36.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6949_CR139","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"1","key":"6949_CR140","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","volume":"12","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6949_CR141","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"6949_CR142","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310793121","volume":"121","author":"J Yang","year":"2024","unstructured":"Yang J, Butti R, Cohn S, Toffessi-Tcheuyap V, Mal A, Nguyen M, et al. Unconventional mechanism of action and resistance to rapalogs in renal cancer. Proc Natl Acad Sci U S A. 2024;121(25): e2310793121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6949_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188942","volume":"1878","author":"V Mieville","year":"2023","unstructured":"Mieville V, Griffioen AW, Benamran D, Nowak-Sliwinska P. Advanced in vitro models for renal cell carcinoma therapy design. Biochim Biophys Acta Rev Cancer. 2023;1878(5): 188942.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"6949_CR144","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41419-020-2486-0","volume":"11","author":"J Gu","year":"2020","unstructured":"Gu J, Zhang Y, Han Z, Gao L, Cui J, Sun Y, et al. Targeting the ERbeta\/angiopoietin-2\/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen faslodex to increase the sunitinib sensitivity in RCC. Cell Death Dis. 2020;11(5):367.","journal-title":"Cell Death Dis"},{"issue":"6","key":"6949_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100779","volume":"4","author":"PN Nwokoye","year":"2024","unstructured":"Nwokoye PN, Abilez OJ. Bioengineering methods for vascularizing organoids. Cell Rep Methods. 2024;4(6): 100779.","journal-title":"Cell Rep Methods"},{"issue":"5","key":"6949_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000705","volume":"18","author":"Y Shi","year":"2020","unstructured":"Shi Y, Sun L, Wang M, Liu J, Zhong S, Li R, et al. Vascularized human cortical organoids (vOrganoids) model cortical development in vivo. PLoS Biol. 2020;18(5): e3000705.","journal-title":"PLoS Biol"},{"issue":"3\u20134","key":"6949_CR147","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000477436","volume":"204","author":"GA Figtree","year":"2017","unstructured":"Figtree GA, Bubb KJ, Tang O, Kizana E, Gentile C. Vascularized cardiac spheroids as novel 3D in vitro models to study cardiac fibrosis. Cells Tissues Organs. 2017;204(3\u20134):191\u20138.","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"6949_CR148","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/ten.tec.2019.0228","volume":"26","author":"I Pitaktong","year":"2020","unstructured":"Pitaktong I, Lui C, Lowenthal J, Mattson G, Jung WH, Bai Y, et al. Early vascular cells improve microvascularization within 3D cardiac spheroids. Tissue Eng Part C Methods. 2020;26(2):80\u201390.","journal-title":"Tissue Eng Part C Methods"},{"issue":"1","key":"6949_CR149","doi-asserted-by":"publisher","first-page":"20699","DOI":"10.1038\/s41598-022-24945-5","volume":"12","author":"A Bas-Cristobal Menendez","year":"2022","unstructured":"Bas-Cristobal Menendez A, Du Z, van den Bosch TPP, Othman A, Gaio N, Silvestri C, et al. Creating a kidney organoid-vasculature interaction model using a novel organ-on-chip system. Sci Rep. 2022;12(1):20699.","journal-title":"Sci Rep"},{"issue":"4","key":"6949_CR150","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jpha.2018.07.005","volume":"8","author":"W Li","year":"2018","unstructured":"Li W, Khan M, Mao S, Feng S, Lin JM. Advances in tumor-endothelial cells co-culture and interaction on microfluidics. J Pharm Anal. 2018;8(4):210\u20138.","journal-title":"J Pharm Anal"},{"issue":"8","key":"6949_CR151","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrurol.2013.126","volume":"10","author":"MM Centenera","year":"2013","unstructured":"Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013;10(8):483\u20137.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"6949_CR152","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6949_CR153","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188\u2013204 (e22).","journal-title":"Cell"},{"issue":"6","key":"6949_CR154","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HHN Yan","year":"2018","unstructured":"Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23(6):882\u201397 (e11).","journal-title":"Cell Stem Cell"},{"issue":"5","key":"6949_CR155","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2020.10.023","volume":"183","author":"K Kawasaki","year":"2020","unstructured":"Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell. 2020;183(5):1420\u201335 (e21).","journal-title":"Cell"},{"issue":"1","key":"6949_CR156","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41467-020-15155-6","volume":"11","author":"C Calandrini","year":"2020","unstructured":"Calandrini C, Schutgens F, Oka R, Margaritis T, Candelli T, Mathijsen L, et al. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat Commun. 2020;11(1):1310.","journal-title":"Nat Commun"},{"issue":"2","key":"6949_CR157","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cll.2005.01.008","volume":"25","author":"P Argani","year":"2005","unstructured":"Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25(2):363\u201378.","journal-title":"Clin Lab Med"},{"issue":"1","key":"6949_CR158","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1038\/s41467-023-38472-y","volume":"14","author":"BH Vokshi","year":"2023","unstructured":"Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, et al. SMARCB1 regulates a TFCP2L1-MYC Transcriptional Switch Promoting Renal Medullary Carcinoma Transformation and Ferroptosis Resistance. Nat Commun. 2023;14(1):3034.","journal-title":"Nat Commun"},{"issue":"5","key":"6949_CR159","doi-asserted-by":"publisher","first-page":"1777060","DOI":"10.1080\/23723556.2020.1777060","volume":"7","author":"P Msaouel","year":"2020","unstructured":"Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to C-MYC than meets the eye. Mol Cell Oncol. 2020;7(5):1777060.","journal-title":"Mol Cell Oncol"},{"issue":"12","key":"6949_CR160","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","volume":"54","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54(12):1183\u2013204.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"6949_CR161","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96.","journal-title":"Mol Cancer"},{"issue":"2","key":"6949_CR162","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275\u201392.","journal-title":"J Pathol"},{"key":"6949_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122907","volume":"352","author":"S Vijayakumar","year":"2024","unstructured":"Vijayakumar S, Dhakshanamoorthy R, Baskaran A, Sabari Krishnan B, Maddaly R. Drug resistance in human cancers - mechanisms and implications. Life Sci. 2024;352: 122907.","journal-title":"Life Sci"},{"issue":"4","key":"6949_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2021.8177","volume":"46","author":"A Kazama","year":"2021","unstructured":"Kazama A, Anraku T, Kuroki H, Shirono Y, Murata M, Bilim V, et al. Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma. Oncol Rep. 2021;46(4):1\u20138.","journal-title":"Oncol Rep"},{"issue":"1","key":"6949_CR165","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41467-020-14700-7","volume":"11","author":"A Fendler","year":"2020","unstructured":"Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, et al. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020;11(1):929.","journal-title":"Nat Commun"},{"issue":"6","key":"6949_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.883","volume":"12","author":"A Reustle","year":"2022","unstructured":"Reustle A, Menig LS, Leuthold P, Hofmann U, Stuhler V, Schmees C, et al. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin Transl Med. 2022;12(6): e883.","journal-title":"Clin Transl Med"},{"issue":"16","key":"6949_CR167","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3390\/cancers13163978","volume":"13","author":"M Rausch","year":"2021","unstructured":"Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, et al. Drug repurposing to identify a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma. Cancers (Basel). 2021;13(16):3978.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6949_CR168","doi-asserted-by":"publisher","first-page":"F33","DOI":"10.1152\/ajprenal.00141.2021","volume":"321","author":"KA Rosette","year":"2021","unstructured":"Rosette KA, Lander SM, VanOpstall C, Looyenga BD. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma. Am J Physiol Renal Physiol. 2021;321(1):F33\u201346.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"6949_CR169","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933\u201345.","journal-title":"Cell"},{"issue":"11","key":"6949_CR170","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5(11):1351\u201377.","journal-title":"Med"},{"key":"6949_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110802","volume":"206","author":"L Cai","year":"2025","unstructured":"Cai L, Chen K, Pan Q, Zhang X, Liu R, Liu Y, et al. Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma. Radiother Oncol. 2025;206: 110802.","journal-title":"Radiother Oncol"},{"issue":"1","key":"6949_CR172","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","volume":"25","author":"S Siva","year":"2024","unstructured":"Siva S, Louie AV, Kotecha R, Barber MN, Ali M, Zhang Z, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the international society of stereotactic radiosurgery (ISRS). Lancet Oncol. 2024;25(1):e18\u201328.","journal-title":"Lancet Oncol"},{"key":"6949_CR173","doi-asserted-by":"publisher","first-page":"1428584","DOI":"10.3389\/fimmu.2024.1428584","volume":"15","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Yang T, Li Y, Qu P, Shao Z, Wang Y, et al. A Future Directions of Renal Cell Carcinoma Treatment: Combination of Immune Checkpoint Inhibition and Carbon Ion Radiotherapy. Front Immunol. 2024;15:1428584.","journal-title":"Front Immunol"},{"issue":"1","key":"6949_CR174","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40001-024-01678-x","volume":"29","author":"X Jing","year":"2024","unstructured":"Jing X, Qin X, Liu H, Liu H, Wang H, Qin J, et al. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications. Eur J Med Res. 2024;29(1):107.","journal-title":"Eur J Med Res"},{"key":"6949_CR175","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12935-020-01306-8","volume":"20","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Li W, Yan Y, Yao X, Gu W, Zhang H. LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via MiR-577\/CHEK2\/FOXM1 axis. Cancer Cell Int. 2020;20:274.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"6949_CR176","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-21-4128","volume":"82","author":"KS Hsu","year":"2022","unstructured":"Hsu KS, Adileh M, Martin ML, Makarov V, Chen J, Wu C, et al. Colorectal cancer develops inherent radiosensitivity that can be predicted using patient-derived organoids. Cancer Res. 2022;82(12):2298\u2013312.","journal-title":"Cancer Res"},{"issue":"20","key":"6949_CR177","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3390\/cancers14204984","volume":"14","author":"K Pape","year":"2022","unstructured":"Pape K, Lossner AJ, William D, Czempiel T, Beyreuther E, Klimova A, et al. Sensitization of patient-derived colorectal cancer organoids to photon and proton radiation by targeting DNA damage response mechanisms. Cancers (Basel). 2022;14(20):4984.","journal-title":"Cancers (Basel)"},{"key":"6949_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115001","volume":"164","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang H, Fang Y, Tang D, Luo Z. Non-coding RNAs in renal cell carcinoma: implications for drug resistance. Biomed Pharmacother. 2023;164: 115001.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"6949_CR179","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12935-022-02790-w","volume":"22","author":"S Qin","year":"2022","unstructured":"Qin S, Wang Y, Wang P, Lv Q. Molecular mechanism of CircRNAs in drug resistance in renal cell carcinoma. Cancer Cell Int. 2022;22(1):369.","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"6949_CR180","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373\u201386 (e10).","journal-title":"Cell"},{"issue":"9","key":"6949_CR181","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341.","journal-title":"N Engl J Med"},{"issue":"14","key":"6949_CR182","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"6","key":"6949_CR183","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthelemy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6): e001079.","journal-title":"ESMO Open"},{"issue":"8","key":"6949_CR184","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1016\/j.apsb.2022.02.023","volume":"12","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Li S, Zhang S, Wang L, Yuan H, Hu F. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm Sin B. 2022;12(8):3233\u201354.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"6949_CR185","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"6949_CR186","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7432","volume":"13","author":"RT Tse","year":"2024","unstructured":"Tse RT, Wong CY, Ding X, Cheng CK, Chow C, Chan RC, et al. The establishment of kidney cancer organoid line in drug testing. Cancer Med. 2024;13(12): e7432.","journal-title":"Cancer Med"},{"key":"6949_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653358","volume":"12","author":"E Lin","year":"2021","unstructured":"Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, et al. Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma. Front Immunol. 2021;12: 653358.","journal-title":"Front Immunol"},{"issue":"9","key":"6949_CR188","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","volume":"8","author":"T Wang","year":"2018","unstructured":"Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. Cancer Discov. 2018;8(9):1142\u201355.","journal-title":"Cancer Discov"},{"issue":"6","key":"6949_CR189","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","volume":"21","author":"B Beuselinck","year":"2015","unstructured":"Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015;21(6):1329\u201339.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"6949_CR190","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC class i downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6949_CR191","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023;55(5):807\u201319.","journal-title":"Nat Genet"},{"issue":"2","key":"6949_CR192","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.30077","volume":"139","author":"M Ruf","year":"2016","unstructured":"Ruf M, Moch H, Schraml P. PD-L1 Expression Is Regulated by Hypoxia Inducible Factor in Clear Cell Renal Cell expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma Int J Cancer. 2016;139(2):396\u2013403.","journal-title":"Int J Cancer"},{"issue":"4","key":"6949_CR193","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","volume":"70","author":"Y Messai","year":"2016","unstructured":"Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von hippel-lindau gene mutation status. Eur Urol. 2016;70(4):623\u201332.","journal-title":"Eur Urol"},{"issue":"6","key":"6949_CR194","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310821121","volume":"121","author":"X Sun","year":"2024","unstructured":"Sun X, Watanabe T, Oda Y, Shen W, Ahmad A, Ouda R, et al. Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through mhc class I. Proc Natl Acad Sci USA. 2024;121(6): e2310821121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6949_CR195","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terren","year":"2019","unstructured":"Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278.","journal-title":"Front Immunol"},{"issue":"9","key":"6949_CR196","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00109-018-1679-9","volume":"96","author":"J Wang","year":"2018","unstructured":"Wang J, Matosevic S. Adenosinergic signaling as a target for natural killer cell immunotherapy. J Mol Med (Berl). 2018;96(9):903\u201313.","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"6949_CR197","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/cancers17030406","volume":"17","author":"PA Palacios","year":"2025","unstructured":"Palacios PA, Flores I, Cereceda L, Otero FF, Muller M, Brebi P, et al. Patient-derived organoid models for NKT cell-based cancer immunotherapy. Cancers (Basel). 2025;17(3):406.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6949_CR198","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39(9):1190\u2013201.","journal-title":"Cancer Cell"},{"issue":"1","key":"6949_CR199","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.stem.2013.11.010","volume":"14","author":"A Taguchi","year":"2014","unstructured":"Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 2014;14(1):53\u201367.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"6949_CR200","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41578-020-0199-8","volume":"5","author":"EA Aisenbrey","year":"2020","unstructured":"Aisenbrey EA, Murphy WL. Synthetic alternatives to matrigel. Nat Rev Mater. 2020;5(7):539\u201351.","journal-title":"Nat Rev Mater"},{"issue":"9","key":"6949_CR201","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/pmic.200900758","volume":"10","author":"CS Hughes","year":"2010","unstructured":"Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10(9):1886\u201390.","journal-title":"Proteomics"},{"issue":"1","key":"6949_CR202","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-022-00356-6","volume":"10","author":"MA Foo","year":"2022","unstructured":"Foo MA, You M, Chan SL, Sethi G, Bonney GK, Yong WP, et al. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. Biomark Res. 2022;10(1):10.","journal-title":"Biomark Res"},{"issue":"1","key":"6949_CR203","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/s41467-023-38832-8","volume":"14","author":"PJ Tebon","year":"2023","unstructured":"Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, et al. Drug screening at single-organoid resolution via bioprinting and interferometry. Nat Commun. 2023;14(1):3168.","journal-title":"Nat Commun"},{"issue":"4","key":"6949_CR204","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","volume":"159","author":"MNB Ramli","year":"2020","unstructured":"Ramli MNB, Lim YS, Koe CT, Demircioglu D, Tng W, Gonzales KAU, et al. Human pluripotent stem cell-derived organoids as models of liver disease. Gastroenterology. 2020;159(4):1471\u201386 (e12).","journal-title":"Gastroenterology"},{"issue":"9","key":"6949_CR205","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.drudis.2016.07.003","volume":"21","author":"A Skardal","year":"2016","unstructured":"Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today. 2016;21(9):1399\u2013411.","journal-title":"Drug Discov Today"},{"issue":"18","key":"6949_CR206","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.3390\/cancers15184466","volume":"15","author":"A van Rijt","year":"2023","unstructured":"van Rijt A, Stefanek E, Valente K. Preclinical testing techniques: paving the way for new oncology screening approaches. Cancers (Basel). 2023;15(18):4466.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6949_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101368","volume":"32","author":"J Gubala","year":"2024","unstructured":"Gubala J, Mieville V, Benamran D, Tille JC, Valerio M, Nowak-Sliwinska P. Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology. Mol Ther Methods Clin Dev. 2024;32(4): 101368.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"414","key":"6949_CR208","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2017.11.021","volume":"1","author":"MZ Jin","year":"2018","unstructured":"Jin MZ, Han RR, Qiu GZ, Ju XC, Lou G, Jin WL. Organoids: an intermediate modeling platform in precision oncology. Cancer Lett. 2018;1(414):174\u201380.","journal-title":"Cancer Lett"},{"issue":"1","key":"6949_CR209","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13287-022-02950-9","volume":"13","author":"D de Jongh","year":"2022","unstructured":"de Jongh D, Massey EK, consortium V, Bunnik EM. Organoids: a systematic review of ethical issues. Stem Cell Res Ther. 2022;13(1):337.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"6949_CR210","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.stemcr.2023.08.003","volume":"18","author":"TE Ludwig","year":"2023","unstructured":"Ludwig TE, Andrews PW, Barbaric I, Benvenisty N, Bhattacharyya A, Crook JM, et al. ISSCR standards for the use of human stem cells in basic research. Stem Cell Rep. 2023;18(9):1744\u201352.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"6949_CR211","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5483\/BMBRep.2022-0155","volume":"56","author":"D Ha","year":"2023","unstructured":"Ha D, Kong J, Kim D, Lee K, Lee J, Park M, et al. Development of bioinformatics and multi-omics analyses in organoids. BMB Rep. 2023;56(1):43\u20138.","journal-title":"BMB Rep"},{"issue":"1","key":"6949_CR212","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176\u201387.","journal-title":"Cell"},{"issue":"6","key":"6949_CR213","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41589-022-00984-x","volume":"18","author":"K Toshimitsu","year":"2022","unstructured":"Toshimitsu K, Takano A, Fujii M, Togasaki K, Matano M, Takahashi S, et al. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nat Chem Biol. 2022;18(6):605\u201314.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"6949_CR214","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11934-025-01276-2","volume":"26","author":"F Gavi","year":"2025","unstructured":"Gavi F, Sighinolfi MC, Pallotta G, Assumma S, Panio E, Fettucciari D, et al. Multiomics in renal cell carcinoma: current landscape and future directions for precision medicine. Curr Urol Rep. 2025;26(1):44.","journal-title":"Curr Urol Rep"},{"issue":"3","key":"6949_CR215","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","volume":"56","author":"J Hu","year":"2024","unstructured":"Hu J, Wang SG, Hou Y, Chen Z, Liu L, Li R, et al. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression. Nat Genet. 2024;56(3):442\u201357.","journal-title":"Nat Genet"},{"issue":"1","key":"6949_CR216","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41467-022-29577-x","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu Y, Feng J, Wu X, Bai L, Xu W, Zhu L, et al. A proteogenomic analysis of clear cell renal cell carcinoma in a chinese population. Nat Commun. 2022;13(1):2052.","journal-title":"Nat Commun"},{"issue":"6628","key":"6949_CR217","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1126\/science.adg6276","volume":"379","author":"M Wadman","year":"2023","unstructured":"Wadman M. FDA no longer has to require animal testing for new drugs. Science. 2023;379(6628):127\u20138.","journal-title":"Science"},{"issue":"4","key":"6949_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100667","volume":"6","author":"L Zhou","year":"2025","unstructured":"Zhou L, Huang J, Li C, Gu Q, Li G, Li ZA, et al. Organoids and organs-on-chips: recent advances, applications in drug development, and regulatory challenges. Med. 2025;6(4): 100667.","journal-title":"Med"},{"issue":"1","key":"6949_CR219","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stemcr.2023.11.008","volume":"19","author":"S Parvatam","year":"2024","unstructured":"Parvatam S, Pamies D, Pistollato F, Beken S, Mariappan I, Roth A, et al. Taking the leap toward human-specific nonanimal methodologies: the need for harmonizing global policies for microphysiological systems. Stem Cell Rep. 2024;19(1):37\u201340.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"6949_CR220","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1039\/D3LC00994G","volume":"24","author":"DR Reyes","year":"2024","unstructured":"Reyes DR, Esch MB, Ewart L, Nasiri R, Herland A, Sung K, et al. From animal testing to in vitro systems: advancing standardization in microphysiological systems. Lab Chip. 2024;24(5):1076\u201387.","journal-title":"Lab Chip"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:05:04Z","timestamp":1761048304000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":220,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6949"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06949-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This article does not contain individual person\u2019sa in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no Conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1152"}}